Technology Prognosis

tracking technologies before you have to make a decision

Luspatercept for Beta-Thalassemia

June 26, 2019

Luspatercept is an erythroid maturation agent administered via subcutaneous injection being developed for the treatment of patients with transfusion-dependent beta-thalassemia. This recombinant fusion protein is believed to help immature cells develop into red blood cells, thereby preventing anemia and reducing or eliminating the need for frequent blood transfusions.